Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
Aggeliki Kontou, Kosmas Sarafidis, Olga Begou, Helen Gika, Alexios Tsiligiannis, Kayode Ogungbenro, Aristides Dokoumetzidis, Eleni Agakidou, Emmanuel Roilides
Abstract
Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the currently recommended dosing regimen in term and preterm neonates. By using an optimal design approach, a prospective PK study was designed and implemented in 60 neonates with postmenstrual ages (PMA) of 26 to 43 weeks. A loading dose of 16 mg/kg was administered at day 1, followed by a maintenance dose of 8 mg/kg daily. Plasma concentrations were quantified by high-pressure liquid chromatography–mass spectrometry.
Topics & Concepts
PharmacokineticsDosingRegimenMedicineTeicoplaninPopulationPopulation pharmacokineticsPharmacologyAnesthesiaInternal medicineVancomycinBiologyEnvironmental healthStaphylococcus aureusBacteriaGeneticsAntibiotics Pharmacokinetics and EfficacyPharmaceutical studies and practicesPneumonia and Respiratory Infections